Skip to main
RBOT
RBOT logo

Vicarious Surgical (RBOT) Stock Forecast & Price Target

Vicarious Surgical (RBOT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Vicarious Surgical Inc has demonstrated effective expense management, with a total operating expense of $17.7 million in Q2 reflecting a 17% decrease year-over-year, which is indicative of the company's commitment to financial discipline. The company's research and development expenditures of $8.5 million were significantly lower than projected, suggesting more efficient use of resources in advancing technology. Moreover, the reaffirmation of the timeline for the Vicarious Surgical Robotic System's version 1.0 integration by fall 2024 underscores management's confidence in their technological advancements and projected commercialization goals.

Bears say

Vicarious Surgical Inc reported significant adjusted net losses in both the latest quarter and prior quarter, underscoring its struggles with profitability as the adjusted EPS of -$2.86 fell short of the Street's expectation of -$2.72. Elevated investment risk associated with the ongoing development of its surgical robot, coupled with concerns around potential future share dilution from equity financings, adds to the company’s financial challenges. The reduction in the company’s cash balance and increased share count also contributed to a lowered price target, reflecting a cautious outlook on long-term viability.

Vicarious Surgical (RBOT) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vicarious Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vicarious Surgical (RBOT) Forecast

Analysts have given Vicarious Surgical (RBOT) a Buy based on their latest research and market trends.

According to 6 analysts, Vicarious Surgical (RBOT) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vicarious Surgical (RBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.